Expressed on TAMs in various malignancies, including colorectal, pancreatic, ovarian, breast, and renal cancers, B7-H4 is clinically significant due to its association with adverse indicators of tumor aggressiveness [134–136]. Here, VTCN1 is linked to neoplasm.